Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE
MinuteCE®

Optimizing Ovarian Function Suppression in Hormone Receptor-Positive Breast Cancer: Best Practices for the Community Clinician

4 episodes
0.50 program credits
28m
MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Program Post-Test
Program Post-Test Completed
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters

  • Overview

    This CME activity explores best practices for ovarian function suppression (OFS) in premenopausal women with hormone receptor-positive (HR+) early-stage breast cancer. Expert faculty review recent clinical data, guideline updates, and real-world evidence to optimize OFS initiation, duration, and integration with other therapies. Key discussions include the efficacy of GnRH agonists, the impact of OFS on treatment outcomes, and strategies to enhance patient adherence. Through this education, clinicians will gain practical guidance on tailoring OFS to individual patient needs while balancing efficacy, safety, and quality of life. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Virginia Kaklamani, MD, DSc
    Professor of Medicine
    Chair, Breast Cancer Research and Treatment
    UT Health San Antonio
    MD Anderson Cancer Center
    San Antonio, TX 

    Dr. Kaklamani has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: AstraZeneca, Daichi Sankyo, Genetech, Gilead, Lily Menarini, Novartis, Pfizer
    Research: Eisai

    Sandra M. Swain, MD, FACP, FASCO
    Associate Dean for Research Development
    Professor of Medicine
    Georgetown University Medical Center
    Washington, DC 

    Dr. Swain has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: AstraZeneca, Chiba, Genentech, Merck, and Roche.
    Other (Third-party writing): AstraZeneca, SAB Napo Pharmaceuticals
    Other (Steering committee and travel): Roche
    Stock Ownership: Immunome BOD

    Reviewers/Content Planners/Authors:

    • Tim Person has no relevant relationships to disclose.
    • Bing Xu, PhD, has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate recent data and guideline updates regarding the use of ovarian function suppression (OFS) in premenopausal women with HR+ early-stage breast cancer
    • Discuss the optimal timing for OFS initiation relative to local and systemic therapy for HR+ early breast cancer in premenopausal women 
    • Optimize the duration of OFS for HR+ early-stage breast cancer in premenopausal women based on pivotal trial evidence and guideline recommendations 

  • Target Audience

    This activity has been designed to meet the educational needs of medical oncologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with breast cancer. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity

    Global Learning Collaborative (GLC) designates this activity for 0.50 contact hour/0.050 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is UAN JA0006235-0000-25-029-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 0.50 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). Approval is valid until 02/28/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity. with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an independent educational grant from TerSera Therapeutics LLC. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule6 Mar 2025
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended